Chromium
Chromium Picolinate
A trace mineral that enhances insulin sensitivity and may help regulate blood sugar and reduce carbohydrate cravings.
Chromium is an essential trace mineral that plays a key role in insulin signaling and glucose metabolism. It enhances insulin's action by helping move glucose into cells more efficiently. Chromium picolinate is the most studied form and has shown benefits for blood sugar control, particularly in those with insulin resistance. It may also help reduce carbohydrate cravings and support weight management efforts.
Mechanisms of Action
Insulin Signaling
Enhances insulin receptor function
Glucose Uptake
Improves cellular glucose uptake
Lipid Metabolism
May improve lipid profiles
Recommended Dose
200-1000mcg daily
Loading: Not required; consistent daily dosing is key
Optimal Timing
- With meals (especially carb-containing)
- Can split doses with meals
Take with food
Best Form
Chromium Picolinate
Alternatives: Chromium Polynicotinate (niacin-bound), Chromium GTF (glucose tolerance factor)
Picolinate is most studied. Polynicotinate may have slightly better absorption. GTF chromium is from yeast.
Duration
Minimum: 8 weeks
Optimal: 16 weeks
Cycling: Not required
Note: Taking with carbohydrate-containing meals may enhance benefits for blood sugar control.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Blood Sugar Control
Improved fasting glucose and HbA1c
Reduced Cravings
Decreased carbohydrate and sugar cravings
Insulin Sensitivity
Enhanced insulin response
May help with glucose control; monitor blood sugar and adjust meds with doctor
Who Should NOT Take This
- Chromate or leather allergy (rare cross-reaction)
Drug Interactions
May enhance blood sugar lowering; monitor glucose
Take at least 3-4 hours apart
Possible Side Effects
Tip: Usually transient
Warnings
- May affect blood sugar; diabetics should monitor closely
- Concerns about high-dose chromium picolinate and DNA are theoretical
Top studies from 40+ peer-reviewed papers
Zhao G et al. • Reproductive biology and endocrinology : RB&E (2025)
“Chromium, inositol, and Omega-3 were found to be beneficial for improving lipid profile.”
Key Findings:
- Inositol significantly decreased total cholesterol and triglyceride levels, while curcumin was most effective in improving low-density and high-density lipoprotein cholesterol levels.
- Chromium, inositol, and Omega-3 were found to be beneficial for improving lipid profile.
- For improving obesity, sex hormone levels, inflammatory factors and oxidative stress indicators of PCOS patients, carnitine, chromium, and soy isoflavones are effective options, respectively.
- These findings confirm that nutritional supplements can effectively alleviate PCOS symptoms, potentially providing valuable guidance for the clinical selection of appropriate nutritional interventions.
Xia J et al. • Pharmacological research (2023)
“All rights reserved.”
Key Findings:
- Low to very low certainty evidence established chromium supplements as the most effective in reducing fasting blood glucose levels and homeostasis model assessment of insulin resistance (SUCRAs: 90.4% and 78.3%, respectively).
- Vitamin K supplements ranked best in reducing glycated hemoglobin A1c and fasting insulin levels (SUCRAs: 97.0% and 82.3%, respectively), with moderate to very low certainty evidence.
- Vanadium supplements ranked best in lowering total cholesterol levels with very low evidence certainty (SUCRAs:100%).
- Niacin supplements ranked best in triglyceride reductions and increasing high-density lipoprotein cholesterol levels with low to very low evidence certainty (SUCRAs:93.7% and 94.6%, respectively).
Hu X et al. • PeerJ (2023)
“Carnitine was relatively effective in reducing body mass, while chromium, Omega-3, and selenium were beneficial for improving glucose metabolism.”
Key Findings:
- The network meta-analysis showed that carnitine, inositol, and probiotics reduced body weight and body mass index (BMI) compared to placebo, and carnitine outperformed the other supplements (SUCRAs: 96.04%, 97.73%, respectively).
- Omega-3 lowered fasting blood glucose (FBG) (SUCRAs: 93.53%), and chromium reduced fasting insulin (FINS) (SUCRAs: 72.90%); both were superior to placebo in improving insulin resistance index (HOMA-IR), and chromium was more effective than Omega-3 (SUCRAs: 79.99%).
- Selenium was potent in raising the quantitative insulin sensitivity index (QUICKI) (SUCRAs: 87.92%).
- Coenzyme Q10 was the most effective in reducing triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels (SUCRAs: 87.71%, 98.78%, and 98.70%, respectively).
Alinaghi F et al. • Contact dermatitis (2023)
“Published by John Wiley & Sons Ltd.”
Key Findings:
- The pooled proportion (95% confidence interval) of Co, Cr and Ni in European metalworkers with dermatitis referred to patch test clinics was 8.2% (5.3%-11.7%), 8.0% (5.1%-11.4%), and 11.0% (7.3%-15.4%), respectively.
- The corresponding estimates for unselected metalworkers from workplace studies were 4.9% (2.4%-8.1%), 5.2% (1.0%-12.6%), and 7.6% (3.8%-12.6%), respectively.
- In comparison, the prevalence of metal allergy in 13 382 consecutive European males with dermatitis was 3.9% (3.6%-4.2%), 4.4% (4.1%-4.8%) and 6.7% (6.3%-7.0%) for Co, Cr and Ni, respectively.
Watanabe H et al. • JAMA cardiology (2022)
“In patients with ACS with successful PCI, clopidogrel monotherapy after 1 to 2 months of DAPT failed to attest noninferiority to standard 12 months of DAPT for the net clinical benefit with a numerical increase in cardiovascular events despite reduction in bleeding events.”
Key Findings:
- Of the 4136 included patients, the mean (SD) age was 66.8 (11.9) years, and 856 (21%) were women, 2324 (56%) had ST-segment elevation MI, and 826 (20%) had non-ST-segment elevation MI.
- A total of 4107 patients (99.3%) completed the 1-year follow-up in June 2021.
- The major secondary cardiovascular end point occurred in 56 patients (2.8%) in the 1- to 2-month DAPT group and in 38 patients (1.9%) in the 12-month DAPT group (absolute difference, 0.90% [95% CI, -0.02% to 1.82%]; HR, 1.50 [95% CI, 0.99-2.26]).
- The major secondary bleeding end point occurred in 11 patients (0.5%) in the 1- to 2-month DAPT group and 24 patients (1.2%) in the 12-month DAPT group (absolute difference, -0.63% [95% CI, -1.20% to -0.06%]; HR, 0.46 [95% CI, 0.23-0.94]).
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.